FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3179959033> ?p ?o ?g. }

• W3179959033 endingPage "1738" @default.
• W3179959033 startingPage "1731" @default.
• W3179959033 abstract "Objective Patients with coronary artery disease (CAD) and atrial fibrillation (AF) can be treated with multiple antithrombotic therapies including antiplatelet and anticoagulant therapies; however, this has the potential to increase bleeding risk. Here, we aimed to evaluate the efficacy and safety of P2Y 12 inhibitors and aspirin in patients also receiving anticoagulant therapy. Methods We evaluated patients from the Atrial Fibrillation and Ischaemic Events with Rivaroxaban in Patients with Stable Coronary Artery Disease (AFIRE) trial who received rivaroxaban plus an antiplatelet agent; the choice of antiplatelet agent was left to the physician’s discretion. The primary efficacy and safety end points, consistent with those of the AFIRE trial, were compared between P2Y 12 inhibitors and aspirin groups. The primary efficacy end point was a composite of stroke, systemic embolism, myocardial infarction, unstable angina requiring revascularisation or death from any cause. The primary safety end point was major bleeding according to the International Society on Thrombosis and Haemostasis criteria. Results A total of 1075 patients were included (P2Y 12 inhibitor group, n=297; aspirin group, n=778). Approximately 60% of patients were administered proton pump inhibitors (PPIs) and there was no significant difference in PPI use in the groups. There were no significant differences in the primary end points between the groups (efficacy: HR 1.31; 95% CI 0.88 to 1.94; p=0.178; safety: HR 0.79; 95% CI 0.43 to 1.47; p=0.456). Conclusions There were no significant differences in cardiovascular and bleeding events in patients with AF and stable CAD taking rivaroxaban with P2Y 12 inhibitors or aspirin in the chronic phase. Trial registration number UMIN000016612; NCT02642419 ." @default.
• W3179959033 created "2021-07-19" @default.
• W3179959033 creator A5001421629 @default.
• W3179959033 creator A5001574933 @default.
• W3179959033 creator A5014759209 @default.
• W3179959033 creator A5020090012 @default.
• W3179959033 creator A5022030714 @default.
• W3179959033 creator A5023792530 @default.
• W3179959033 creator A5037592709 @default.
• W3179959033 creator A5046761063 @default.
• W3179959033 creator A5058793966 @default.
• W3179959033 creator A5063616074 @default.
• W3179959033 creator A5067878206 @default.
• W3179959033 creator A5079485654 @default.
• W3179959033 creator A5082589032 @default.
• W3179959033 date "2021-07-14" @default.
• W3179959033 modified "2023-10-16" @default.
• W3179959033 title "Aspirin versus P2Y12 inhibitors with anticoagulation therapy for atrial fibrillation" @default.
• W3179959033 cites W2052595201 @default.
• W3179959033 cites W2117559770 @default.
• W3179959033 cites W2159370853 @default.
• W3179959033 cites W2320128544 @default.
• W3179959033 cites W2556417520 @default.
• W3179959033 cites W2560004679 @default.
• W3179959033 cites W2647552175 @default.
• W3179959033 cites W2749929702 @default.
• W3179959033 cites W2792735509 @default.
• W3179959033 cites W2802835447 @default.
• W3179959033 cites W2884532285 @default.
• W3179959033 cites W2912772408 @default.
• W3179959033 cites W2921724943 @default.
• W3179959033 cites W2936489929 @default.
• W3179959033 cites W2949986921 @default.
• W3179959033 cites W2953479758 @default.
• W3179959033 cites W2955952534 @default.
• W3179959033 cites W2972299172 @default.
• W3179959033 cites W2976166882 @default.
• W3179959033 cites W2981795354 @default.
• W3179959033 cites W2988553011 @default.
• W3179959033 cites W3010342134 @default.
• W3179959033 cites W3012340745 @default.
• W3179959033 cites W3013680585 @default.
• W3179959033 cites W3023873851 @default.
• W3179959033 cites W3082188176 @default.
• W3179959033 cites W3091874256 @default.
• W3179959033 cites W3094823953 @default.
• W3179959033 cites W311320695 @default.
• W3179959033 cites W4241450225 @default.
• W3179959033 doi "https://doi.org/10.1136/heartjnl-2021-319321" @default.
• W3179959033 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34261738" @default.
• W3179959033 hasPublicationYear "2021" @default.
• W3179959033 type Work @default.
• W3179959033 sameAs 3179959033 @default.
• W3179959033 citedByCount "1" @default.
• W3179959033 countsByYear W31799590332021 @default.
• W3179959033 crossrefType "journal-article" @default.
• W3179959033 hasAuthorship W3179959033A5001421629 @default.
• W3179959033 hasAuthorship W3179959033A5001574933 @default.
• W3179959033 hasAuthorship W3179959033A5014759209 @default.
• W3179959033 hasAuthorship W3179959033A5020090012 @default.
• W3179959033 hasAuthorship W3179959033A5022030714 @default.
• W3179959033 hasAuthorship W3179959033A5023792530 @default.
• W3179959033 hasAuthorship W3179959033A5037592709 @default.
• W3179959033 hasAuthorship W3179959033A5046761063 @default.
• W3179959033 hasAuthorship W3179959033A5058793966 @default.
• W3179959033 hasAuthorship W3179959033A5063616074 @default.
• W3179959033 hasAuthorship W3179959033A5067878206 @default.
• W3179959033 hasAuthorship W3179959033A5079485654 @default.
• W3179959033 hasAuthorship W3179959033A5082589032 @default.
• W3179959033 hasConcept C126322002 @default.
• W3179959033 hasConcept C127413603 @default.
• W3179959033 hasConcept C164705383 @default.
• W3179959033 hasConcept C168563851 @default.
• W3179959033 hasConcept C203092338 @default.
• W3179959033 hasConcept C2776301958 @default.
• W3179959033 hasConcept C2777015399 @default.
• W3179959033 hasConcept C2777628954 @default.
• W3179959033 hasConcept C2777785093 @default.
• W3179959033 hasConcept C2777849778 @default.
• W3179959033 hasConcept C2778213512 @default.
• W3179959033 hasConcept C2778661090 @default.
• W3179959033 hasConcept C2779161974 @default.
• W3179959033 hasConcept C2780645631 @default.
• W3179959033 hasConcept C500558357 @default.
• W3179959033 hasConcept C71924100 @default.
• W3179959033 hasConcept C78519656 @default.
• W3179959033 hasConceptScore W3179959033C126322002 @default.
• W3179959033 hasConceptScore W3179959033C127413603 @default.
• W3179959033 hasConceptScore W3179959033C164705383 @default.
• W3179959033 hasConceptScore W3179959033C168563851 @default.
• W3179959033 hasConceptScore W3179959033C203092338 @default.
• W3179959033 hasConceptScore W3179959033C2776301958 @default.
• W3179959033 hasConceptScore W3179959033C2777015399 @default.
• W3179959033 hasConceptScore W3179959033C2777628954 @default.
• W3179959033 hasConceptScore W3179959033C2777785093 @default.
• W3179959033 hasConceptScore W3179959033C2777849778 @default.
• W3179959033 hasConceptScore W3179959033C2778213512 @default.
• W3179959033 hasConceptScore W3179959033C2778661090 @default.

• next